Rewriting the Code

New Frontiers in tRNA Modification and Epigenetic Regulation of Cellular Protein Synthesis

Azadyne

Azadyne is a UK company founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon & J Michael Southern. It is a spin-out from Trinity College Dublin, to exploit the pioneering work conducted in the Profs Kelly, Connon & Southern’s labs.

The company has received investment from VC and EIS investors.

Azadyne is a pre-clinical stage company exploiting a novel drug target and pathway with numerous potential applications

Key Features

Azadyne’s novel and innovative approach to treating disease is characterized by some key features:

A novel target

Highly selective pathway

Selective modification of specific tRNAs

Efficacy in multiple models/multiple diseases/including human samples

Effects multiple components of response

Safe and well tolerated in vivo

Multiple Chemical series with oral bioavailability